Synmosa Biopharma (4114.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · Taiwan · ISIN TW0004114004

Price
27.70 TWD
Market cap
14.13 bn TWD
P/E (2025)
–
P/S (2025)
2.28
Dividend yield
3.06 %
Net margin
13.28 %
Return on equity (ROE)
8.14 %
Return on assets (ROA)
5.88 %

Synmosa Biopharma financials

Fiscal year20242025
Revenue5.55 bn TWD6.19 bn TWD
Gross profit2.40 bn TWD2.68 bn TWD
Operating income739.08 m TWD777.94 m TWD
EBIT717.17 m TWD861.70 m TWD
Net income684.68 m TWD821.85 m TWD

Full history since 2015, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Synmosa Biopharma

Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally. It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, granules, and nasal sprays. The company is also involved in provision of cosmetics, veterinary drugs, chemical food additives, and beverages; wholesale retail of environmental drugs; and import and export of related businesses. The company was founded in 1959 and is based in Taipei, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.